Efficacy and Safety of Combination Therapy for Schistosomiasis in Kenyan Children
Introduction
Reliance on praziquantel for treating schistosomiasis may lead to drug resistance. We evaluated the efficacy and safety of combining praziquantel with artesunate plus sulfalene-pyrimethamine in Kenyan children with schistosomiasis.
Methods
426 children aged 7-15 were randomly assigned to receive praziquantel alone, artesunate plus sulfalene-pyrimethamine alone, or a combination of both. Cure and egg reduction rates were assessed 6 weeks post-treatment, and adverse events were monitored.
Results
The combination therapy showed promising results, with higher cure rates for S. haematobium-infected children compared to the individual treatments. Adverse events were mild, and no serious adverse events were reported.
Conclusions
Combining praziquantel with artesunate plus sulfalene-pyrimethamine may enhance treatment efficacy and safety outcomes for schistosomiasis in children.
Practical Solutions and Value
Streamlining Operations
Our AI-driven platform, DocSym, consolidates clinical standards and research, making it easier for clinicians to access essential knowledge. Mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining patient care and expanding digital services.
Enhancing Workflows with AI
AI can improve clinic workflows, reduce paperwork, and enhance patient outcomes. Visit aidevmd.com to learn more about how we can help.
